P1354: CRISPR/CAS9 GENE EDITING OF IMMUNE CHECKPOINT RECEPTOR NKG2A IMPROVES THE ANTI-LEUKEMIC EFFICACY OF PRIMARY CD33-TARGETING CAR-NK CELLS.

Documenti analoghi

• P1354: CRISPR/CAS9 GENE EDITING OF IMMUNE CHECKPOINT RECEPTOR NKG2A IMPROVES THE ANTI-LEUKEMIC EFFICACY OF PRIMARY CD33-TARGETING CAR-NK CELLS.
  di: Nawid Albinger, et al.
  Pubblicazione: (2023-08-01)
• CRISPR-Cas9 based gene editing of the immune checkpoint NKG2A enhances NK cell mediated cytotoxicity against multiple myeloma
  di: Tobias Bexte, et al.
  Pubblicazione: (2022-12-01)
• Engineering with care: safety assessment platforms for CRISPR-modified natural killer cells
  di: Alieh Fazeli, et al.
  Pubblicazione: (2025-12-01)
• Characterization of BV6-Induced Sensitization to the NK Cell Killing of Pediatric Rhabdomyosarcoma Spheroids
  di: Vinzenz Särchen, et al.
  Pubblicazione: (2023-03-01)
• Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia
  di: Nawid Albinger, et al.
  Pubblicazione: (2022-04-01)